Literature DB >> 15170332

Quantitative binding models for CYP2C9 based on benzbromarone analogues.

Charles W Locuson1, Denise A Rock, Jeffrey P Jones.   

Abstract

The cytochrome P450 (CYP) isoforms involved in xenobiotic metabolism are enzymes whose substrate selectivity remains difficult to predict due to wide specificity and dynamic protein-substrate interactions. To uncover the determinants of specificity for cytochrome CYP2C9, a novel library of benzbromarone (bzbr) inhibitors was used to reevaluate its pharmacophore. CoMSIA was used with the bzbr ligands to generate both quantitative binding models and three-dimensional contour plots that pinpoint predicted interactions that are important for binding to 2C9. Since this class of compounds is more potent than any other toward 2C9, the small molecule properties deemed most ideal by the software were used to address protein-ligand interactions using new mutagenesis and structural data. Nine new bzbr analogues provide evidence that specific electrostatic and hydrophobic interactions contribute the most to 2C9's specificity. Three of the new analogues are better isosteres of bzbr that contain bulky groups adjacent to the phenol and have increased pK(a) values. These ligands test the hypothesis that anionic substrates bind with higher affinity to 2C9. Since they have higher affinity than the previous nonacidic analogues, the importance of bulky groups on the phenol ring appears to have been underestimated. CoMSIA models predict that these bulky groups are favorable for their hydrophobicity, while a negative charge is favored at the ketone oxygen rather than the phenol oxygen. The overlap of this ketone with electronegative groups of other 2C9 substrates suggests they act as key positive charge acceptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170332     DOI: 10.1021/bi049651o

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  Exploration of the binding of curcumin analogues to human P450 2C9 based on docking and molecular dynamics simulation.

Authors:  Rongwei Shi; Yin Wang; Xiaolei Zhu; Xiaohua Lu
Journal:  J Mol Model       Date:  2011-11-12       Impact factor: 1.810

2.  CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant.

Authors:  Matthew A Hummel; Charles W Locuson; Peter M Gannett; Dan A Rock; Carrie M Mosher; Allan E Rettie; Timothy S Tracy
Journal:  Mol Pharmacol       Date:  2005-06-13       Impact factor: 4.436

3.  Line-walking method for predicting the inhibition of P450 drug metabolism.

Authors:  Matthew G Hudelson; Jeffrey P Jones
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

4.  Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety.

Authors:  Gang Xie; Chi C Wong; Ka-Wing Cheng; Liqun Huang; Panayiotis P Constantinides; Basil Rigas
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

5.  Cytochrome P450 2C9 type II binding studies on quinoline-4-carboxamide analogues.

Authors:  Chi-Chi Peng; Jonathan L Cape; Tom Rushmore; Gregory J Crouch; Jeffrey P Jones
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

6.  High-throughput screening of a collection of known pharmacologically active small compounds for identification of Candida albicans biofilm inhibitors.

Authors:  Samuel A Siles; Anand Srinivasan; Christopher G Pierce; José L Lopez-Ribot; Anand K Ramasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

Review 7.  Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms.

Authors:  Johannes Kirchmair; Mark J Williamson; Jonathan D Tyzack; Lu Tan; Peter J Bond; Andreas Bender; Robert C Glen
Journal:  J Chem Inf Model       Date:  2012-02-17       Impact factor: 4.956

8.  Structural Basis of Single-Nucleotide Polymorphisms in Cytochrome P450 2C9.

Authors:  Keiko Maekawa; Motoyasu Adachi; Yumiko Matsuzawa; Qinghai Zhang; Ryota Kuroki; Yoshiro Saito; Manish B Shah
Journal:  Biochemistry       Date:  2017-10-03       Impact factor: 3.162

Review 9.  Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies.

Authors:  Jayalakshmi Sridhar; Jiawang Liu; Maryam Foroozesh; Cheryl L Klein Stevens
Journal:  Molecules       Date:  2012-08-03       Impact factor: 4.411

10.  The curious case of benzbromarone: insight into super-inhibition of cytochrome P450.

Authors:  Abhinav Parashar; Sudeep Kumar Gade; Mahesh Potnuru; Nandita Madhavan; Kelath Murali Manoj
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.